{
    "code": "02024834",
    "url": "https:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02024834",
    "time": "2018-01-19 03:16:37",
    "許可證字號": "衛署藥輸字第024834號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "112\/05\/12",
    "發證日期": "97\/05\/12",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202483409",
    "中文品名": "泰息安 膠囊 200 毫克",
    "英文品名": "Tasigna Capsules 200 mg",
    "適應症": "治療慢性期及加速期費城染色體(Philadelphia chromosome)陽性的慢性骨髓性白血病(CML)成年患者，且該患者至少有過一次對先前的治療(包括imatinib)有阻抗性或耐受性不良的經驗。",
    "劑型": "130膠囊劑",
    "包裝": "8~1000粒鋁箔盒裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "主成分略述": [
        "NILOTINIBHYDROCHLORIDEMONOHYDRATE"
    ],
    "限制項目": "02輸　入 58依本署891212衛署藥字第0890035812號公告經本署認定得免除國內銜接性試驗且經本署核定之新藥",
    "申請商名稱": "0924601100  台灣諾華股份有限公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F430088000  NOVARTIS PHARMA STEIN AG",
        "製造廠廠址": "SCHAFFHAUSERSTRASSE CH-4332 STEIN, SWITZERLAND",
        "製造廠公司地址": ""
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "次製造廠": [
        {
            "製造廠名稱": "F430088200  NOVARTIS PHARMA AG",
            "製造廠廠址": "LICHTSTRASSE 35 CH-4056 BASEL SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "許可證持有者"
        }
    ],
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013001920",
            "成分名稱": "NILOTINIB HYDROCHLORIDE MONOHYDRATE",
            "含量描述": "(= Nilotinib 200.0 m",
            "含量": "220.6000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Tasigna_TWI-070217_C-106-02-14.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024834&Seq=020&Type=9"
        },
        {
            "title": "Tasigna 200mg-104-09-11(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02024834&Seq=007&Type=8"
        }
    ]
}